Our data suggested that ß-arr2 was critical for ERK activation, and the combination of CP with ß-arr2 KD dramatically decreased the pERK below the detection level of Western blot, indicating potential therapeutic values to combine CP with ß-arr2 inhibitor to treat SCLC. This evidence concerns the gene EIF2AK3 and small cell lung carcinoma.